Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATP in moderate to severe depression
NCT06266715Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in major depressive disorder (MDD) comparing ATP Group with Placebo Group (2 arms). Primary endpoint: Hamilton Depression Scale at 4 weeks. Started Mar 2024; status: recruiting.
02
Drugs
adenosine 5'-triphosphate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06266715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266715.